Loading
Every dated change on the records linked to Resectable pancreatic ductal adenocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Alive at 18 months: 60 percent with neoadjuvant FOLFIRINOX against 73 percent with upfront surgery (p 0.
A milestone in how this cancer is treated.
Independently assessed disease-free survival 19.
Vaccine-induced T cells in 8 of 16 patients; median recurrence-free survival not reached in responders against 13.
18-month disease-free survival 33.
A milestone in how this cancer is treated.